Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 

Though TAVR was once never considered a treatment option for younger patients, it is becoming more common as time goes on. 

Here are links to more information for all the late-breaking presentations at the 2022 Transcatheter Valve Therapies (TVT) Structural Heart Summit.

Researchers tracked both short- and long-term outcomes, sharing their findings in the Journal of the American Heart Association.

When discussing the possibility of TAVR for a patient with COPD, it is crucial to consider the severity of their symptoms.  

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

The trial is expected to enroll up to 650 patients from as many as 100 different facilities throughout the world.